Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

y not warrant further development of this compound for the treatment of chronic hepatitis B and completing our clinical studies may take longer or cost more than expected. In addition, feedback from regulatory authorities or results from clinical trials might require modifications or delays in later stage clinical trials or additional trials to be performed. Further, the FDA and other regulatory authorities may not approve tenofovir DF for the treatment of chronic hepatitis B, and marketing approval, if granted, may have significant limitations on its use and physicians and may not see advantages of tenofovir DF over other treatment options and may therefore be reluctant to prescribe tenofovir DF for chronic hepatitis B. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Quarterly Report on Form 10-Q for the first quarter of 2007, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Hepsera and Viread are registered trademarks of Gilead Sciences, Inc.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.


CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
James Loduca, 650-522-5908 (Media)
www.gilead.com

SOURCE: Gilead Sciences, Inc.



'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... DUBLIN , May 22, 2015 Research ... announced the addition of the "Latest Regulations ... report to their offering. This ... officially issued a guidance on international multi-center clinical ... , which has begun to be implemented on ...
(Date:5/22/2015)... -- Richmond Pharmacology is a university ... worldwide reputation for excellence in clinical trials. It ... reviewed medical journals. Its officers are engaged with ... about rules for transparency and publication of clinical ... Clinical research is conducted worldwide, therefore ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... Md. , May 26 The U.S. Food and Drug Administration ... liver injury in patients taking the weight-loss medication orlistat, marketed as Xenical and ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ... The FDA has approved a ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it will present at ... on June 9, 2010 , in New York, NY . ... provide an update on the Company,s marketed products and clinical programs. , ... The presentation will be webcast. To access ...
Cached Medicine Technology:FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 2FDA: Rare Cases of Liver Injury Reported With Use of Xenical, Alli 3ISTA Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:5/22/2015)... VIEW, California (PRWEB) May 22, 2015 Coco ... has set a RecordSetter.com World Record at the 104th running ... Libre coconut water ice luge served 315 people in one ... Bay to Breakers race is so true to the heart ... we felt bringing an ice luge to the finish line ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all ... company specialize in include decks, additions, kitchen remodeling, interior ... much more. , The redesigned logo is a ... company. It includes two geometrical lines that represent the ... to be used with many things associated with the ...
(Date:5/22/2015)... 22, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing , is proud ... respected All American National athlete, to the Wimbledon Athletics ... the high level of testing and information it provides ... their athletic trainers, this way they can focus on ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... of Multifamily Housing, Marc Zuluaga, has been selected by ... innovative engineering. The award winners are featured in the ... given to 40 building industry professionals age 40 and ... to the building community, as well as in other ...
(Date:5/22/2015)... 2015 Bryce Henson, local fitness icon ... Boot Camp, recently accepted his program’s 100th client. Henson ... launch of his location evidences the powerful impact his ... Fit Body Boot Camp is the nation’s most popular ... hundreds of locations across North America, Europe and Australia. ...
Breaking Medicine News(10 mins):Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2
... Preclinical Data Indicate New HspE7 Promotes More ... Nov. 5 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) ... at the 24th International Papillomavirus,conference, the largest ... in the field of human papillomavirus (HPV), ...
... Corp. (OTC Bulletin,Board: CRDT), a leading healthcare staffing ... to Vice President of Operations of Crdentia,s,newly acquired ... Mr. Jones joins Crdentia from ATS Health ... health staffing services with six offices in,Florida, one ...
... care insurance provides important financial protection and peace ... of mind for ... Treaty American,Corporation, a pioneer in the long-term care insurance (LTCi) ... awareness of,long-term care options during the month of November. ...
... Nov. 5 ,Following consultation with the German Federal ... Food and Drug Administration (FDA),Health Canada, and other ... to temporarily suspend worldwide marketing of Trasylol(R),(aprotinin injection) ... can,be compiled, received and evaluated. The company took ...
... young inner-city children appears to be more unpredictable than ever, ... wise move as a hedge against dangerous flare-ups of wheezing ... from the Johns Hopkins Childrens Center. Current asthma guidelines call ... six months may be too long for many patients, researchers ...
... better when the dark delight is consumed, study suggests , ... A Japanese study finds that flavonoid-rich dark chocolate can improve ... as coronary flow velocity reserve (CFVR), an indicator of the ... blood flow in response to medications. , The two-week trial ...
Cached Medicine News:Health News:Nventa presents HspE7 data at international HPV conference 2Health News:Nventa presents HspE7 data at international HPV conference 3Health News:Nventa presents HspE7 data at international HPV conference 4Health News:Nventa presents HspE7 data at international HPV conference 5Health News:Crdentia Announces Appointment of Tim Jones to Senior Management Team 2Health News:Crdentia Announces Appointment of Tim Jones to Senior Management Team 3Health News:Penn Treaty Urges Americans To Plan for Their Future During Long-Term Care Awareness Week 2Health News:Penn Treaty Urges Americans To Plan for Their Future During Long-Term Care Awareness Week 3Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 2Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 3Health News:Bayer Temporarily Suspends Global Trasylol(R) Marketing 4Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Chocolate Has Sweet Effect on Blood Flow 2
... Post Operative Pin® Knee Brace (DxHDDLP) has a ... drop lock lever and laminate liner. The precision ... brace from migrating on the leg during ambulation. ... that controls flexion and extension in 5° increments ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
... The Drytex Adjustable Patella Donut ... a unique nylon core and polyester ... airflow. A trimable full-circumference donut provides ... who have neoprene based allergies or ...
... for total knees, meniscus repairs, regenerative chondroplasty, ... TROM gives easy-to-use range of motion control ... Rehab TROM can be used as a ... purchased separately be used with the TROM ...
Medicine Products: